LIGAND PHARMACEUTICALS INC

For the period ended Jun 30, 2026. Filed Aug 7, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 7, 2026

LGND$314.16+0.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except par value)

	June 30, 2026	December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents	$1,006,702	$174,927
Short-term investments	351,056	558,594
Accounts receivable, net	67,011	59,601
Inventory	10,263	9,126
Short-term portion of financial royalty assets, net	12,982	22,792
Income taxes receivable	2,911	1,446
Other current assets	6,191	5,785
Total current assets	1,457,116	832,271
Intangible assets, net	209,244	225,438
Goodwill	101,541	101,541
Long-term portion of financial royalty assets, net	194,228	196,877
Noncurrent derivative assets	17,913	15,632
Equity method investments	42,390	46,500
Other investments	114,483	121,451
Deferred income taxes, net	37,119	8,345
Other assets	11,841	12,582
Total assets	$2,185,875	$1,560,637
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$9,405	$3,238
Accrued liabilities	31,867	31,453
Income taxes payable	3,217	1,239
Current contingent liabilities	210	287
Current operating lease liabilities	1,082	1,095
Other current liabilities	955	135
Total current liabilities	46,736	37,447
Long-term contingent liabilities	2,382	2,934
Long-term operating lease liabilities	3,777	4,204
Convertible senior notes, net	1,126,594	446,192
Deferred income taxes, net	21,654	36,019
Other long-term liabilities	17,216	16,629
Total liabilities	1,218,359	543,425
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at June 30, 2026 and December 31, 2025	—	—
Common stock, $0.001 par value; 60,000 shares authorized; 19,920 and 19,774 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	20	20
Additional paid-in capital	379,769	400,649
Accumulated other comprehensive income	4,476	8,455
Retained earnings	583,251	608,088
Total stockholders’ equity	967,516	1,017,212
Total liabilities and stockholders’ equity	$2,185,875	$1,560,637

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.